Literature DB >> 26165790

Preservation of Biological Activity of Plasma and Platelet-Derived Eye Drops After Their Different Time and Temperature Conditions of Storage.

Eduardo Anitua1, María de la Fuente, Ana Riestra, Jesús Merayo-Lloves, Francisco Muruzábal, Gorka Orive.   

Abstract

PURPOSE: To analyze whether plasma rich in growth factors (PRGF) eye drops preserve their biological characteristics and activity after storage for 3 and 6 months at -20°C, at 4°C, and at room temperature for 72 hours, compared with fresh samples (t0).
METHODS: Blood from 6 healthy donors was harvested and centrifuged to obtain PRGF free of leukocytes. Resulting PRGF eye drops were stored for 3 and 6 months at -20°C. At each time, 2 aliquots were maintained at room temperature or at 4°C for 72 hours. Platelet-derived growth factor-AB, transforming growth factor-β1, vascular endothelial growth factor, epidermal growth factor, insulin-like growth factor-1, angiopoietin-1, and thrombospondin-1 were quantified at each time and temperature of storage. Also, the effect of PRGF eye drops on proliferation of primary human keratocytes was evaluated.
RESULTS: All the analyzed growth factor levels remained constant at each time and storage condition. No differences were observed in the proliferative activity of keratocytes after treatment with PRGF eye drops at any studied time or temperature. Finally, there was no microbial contamination in any of the PRGF eye drops.
CONCLUSIONS: The preservation of the PRGF eye drops at -20°C for up to 3 and 6 months does not mean reduction of the main growth factors and proteins implicated in ocular surface wound healing. Eye drop characteristics and in vitro biological activity were not affected by their usage and conservation for 72 hours at 4°C or at room temperature.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165790     DOI: 10.1097/ICO.0000000000000489

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  9 in total

1.  Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases.

Authors:  Ronald M Sánchez-Ávila; Edmar Uribe-Badillo; Carlos Fernández-Vega González; Francisco Muruzabal; Borja de la Sen-Corcuera; Begoña Baamonde; Luis M Quirós; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Vision (Basel)       Date:  2021-07-02

2.  Short term storage stability at room temperature of two different platelet-rich plasma preparations from equine donors and potential impact on growth factor concentrations.

Authors:  Gregor Hauschild; Florian Geburek; Georg Gosheger; Maria Eveslage; Daniela Serrano; Arne Streitbürger; Sara Johannlükens; Dirk Menzel; Reinhard Mischke
Journal:  BMC Vet Res       Date:  2017-01-05       Impact factor: 2.741

Review 3.  Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products.

Authors:  Victor J Drew; Ching-Li Tseng; Jerard Seghatchian; Thierry Burnouf
Journal:  Front Med (Lausanne)       Date:  2018-02-23

4.  Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF).

Authors:  Eduardo Anitua; María de la Fuente; Francisco Muruzabal; Ronald Mauricio Sánchez-Ávila; Jesús Merayo-Lloves; Mikel Azkargorta; Felix Elortza; Gorka Orive
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

5.  Plasma Rich in Growth Factors in Macular Hole Surgery.

Authors:  Ronald M Sánchez-Ávila; Carlos A Robayo-Esper; Eva Villota-Deleu; Álvaro Fernández-Vega Sanz; Álvaro Fernández-Vega González; Borja de la Sen-Corcuera; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Clin Pract       Date:  2022-01-10

6.  Chitosan-dipotassium orthophosphate lyophilizate: a novel in situ thermogel carrier system of allogeneic platelet lysate growth factors.

Authors:  Toaa A Abdelrahman; Amira Motawea; Marwa S El-Dahhan; Galal M Abdelghani
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

7.  Clinical Response After Treatment of Knee Osteoarthritis With a Standardized, Closed-System, Low-Cost Platelet-Rich Plasma Product: 1-Year Outcomes.

Authors:  Judit Fernández-Fuertes; Tamara Arias-Fernández; Andrea Acebes-Huerta; Marlene Álvarez-Rico; Laura Gutiérrez
Journal:  Orthop J Sports Med       Date:  2022-03-31

8.  Differential Protein Content between Fresh and Freeze-Dried Plasma Rich in Growth Factors Eye Drops.

Authors:  Eduardo Anitua; Ander Pino; Mikel Azkargorta; Felix Elortza; Jesús Merayo-Lloves; Francisco Muruzabal
Journal:  Biomolecules       Date:  2022-09-01

9.  Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology.

Authors:  Eduardo Anitua; María de la Fuente; Ignacio Alcalde; Cristina Sanchez; Jesús Merayo-Lloves; Francisco Muruzabal
Journal:  Transl Vis Sci Technol       Date:  2020-06-25       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.